The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Drugs for Asthma and COPD-Global Market Insights and Sales Trends 2024
Synopsis
Drugs used as treatments for asthma and COPD
The global Drugs for Asthma and COPD market size is expected to reach US$ 68020 million by 2029, growing at a CAGR of 5.8% from 2023 to 2029. The market is mainly driven by the significant applications of Drugs for Asthma and COPD in various end use industries. The expanding demands from the Asthma and COPD, are propelling Drugs for Asthma and COPD market. Inhalable & Nasal Spray, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Oral segment is estimated at % CAGR for the next seven-year period.
The market for drugs used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) is expected to witness substantial growth in the coming years. The increasing prevalence of these respiratory disorders, growing awareness about their diagnosis and management, and advancements in drug therapies are key drivers of market expansion. Bronchodilators and corticosteroids are commonly prescribed medications for asthma and COPD, and the market for these drugs is highly competitive, with several pharmaceutical companies involved in their production and distribution. However, challenges such as high treatment costs, side effects, and the availability of generic alternatives may hinder market growth. Nonetheless, the drugs for asthma and COPD market holds significant opportunities for growth, driven by the rising global burden of these respiratory conditions and the continuous development of novel therapeutic options.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Drugs for Asthma and COPD, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Drugs for Asthma and COPD market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Drugs for Asthma and COPD market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Drugs for Asthma and COPD sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Drugs for Asthma and COPD covered in this report include GSK, AstraZeneca, Boehringer Ingelheim, Vertex, Roche, Novartis, Teva, Chiesi and Mylan, etc.
The global Drugs for Asthma and COPD market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GSK
AstraZeneca
Boehringer Ingelheim
Vertex
Roche
Novartis
Teva
Chiesi
Mylan
Sumitomo Dainippon
Merck
Beximco
Global Drugs for Asthma and COPD market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Drugs for Asthma and COPD market, Segment by Type:
Inhalable & Nasal Spray
Oral
Others
Global Drugs for Asthma and COPD market, by Application
Asthma
COPD
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Drugs for Asthma and COPD companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Drugs used as treatments for asthma and COPD
The global Drugs for Asthma and COPD market size is expected to reach US$ 68020 million by 2029, growing at a CAGR of 5.8% from 2023 to 2029. The market is mainly driven by the significant applications of Drugs for Asthma and COPD in various end use industries. The expanding demands from the Asthma and COPD, are propelling Drugs for Asthma and COPD market. Inhalable & Nasal Spray, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Oral segment is estimated at % CAGR for the next seven-year period.
The market for drugs used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) is expected to witness substantial growth in the coming years. The increasing prevalence of these respiratory disorders, growing awareness about their diagnosis and management, and advancements in drug therapies are key drivers of market expansion. Bronchodilators and corticosteroids are commonly prescribed medications for asthma and COPD, and the market for these drugs is highly competitive, with several pharmaceutical companies involved in their production and distribution. However, challenges such as high treatment costs, side effects, and the availability of generic alternatives may hinder market growth. Nonetheless, the drugs for asthma and COPD market holds significant opportunities for growth, driven by the rising global burden of these respiratory conditions and the continuous development of novel therapeutic options.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Drugs for Asthma and COPD, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Drugs for Asthma and COPD market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Drugs for Asthma and COPD market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Drugs for Asthma and COPD sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Drugs for Asthma and COPD covered in this report include GSK, AstraZeneca, Boehringer Ingelheim, Vertex, Roche, Novartis, Teva, Chiesi and Mylan, etc.
The global Drugs for Asthma and COPD market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GSK
AstraZeneca
Boehringer Ingelheim
Vertex
Roche
Novartis
Teva
Chiesi
Mylan
Sumitomo Dainippon
Merck
Beximco
Global Drugs for Asthma and COPD market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Drugs for Asthma and COPD market, Segment by Type:
Inhalable & Nasal Spray
Oral
Others
Global Drugs for Asthma and COPD market, by Application
Asthma
COPD
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Drugs for Asthma and COPD companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Drugs for Asthma and COPD
1.1 Drugs for Asthma and COPD Market Overview
1.1.1 Drugs for Asthma and COPD Product Scope
1.1.2 Drugs for Asthma and COPD Market Status and Outlook
1.2 Global Drugs for Asthma and COPD Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Drugs for Asthma and COPD Market Size by Region (2018-2029)
1.4 Global Drugs for Asthma and COPD Historic Market Size by Region (2018-2023)
1.5 Global Drugs for Asthma and COPD Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Drugs for Asthma and COPD Market Size (2018-2029)
1.6.1 North America Drugs for Asthma and COPD Market Size (2018-2029)
1.6.2 Europe Drugs for Asthma and COPD Market Size (2018-2029)
1.6.3 Asia-Pacific Drugs for Asthma and COPD Market Size (2018-2029)
1.6.4 Latin America Drugs for Asthma and COPD Market Size (2018-2029)
1.6.5 Middle East & Africa Drugs for Asthma and COPD Market Size (2018-2029)
2 Drugs for Asthma and COPD Market by Type
2.1 Introduction
2.1.1 Inhalable & Nasal Spray
2.1.2 Oral
2.1.3 Others
2.2 Global Drugs for Asthma and COPD Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Drugs for Asthma and COPD Historic Market Size by Type (2018-2023)
2.2.2 Global Drugs for Asthma and COPD Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Drugs for Asthma and COPD Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Drugs for Asthma and COPD Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Drugs for Asthma and COPD Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Drugs for Asthma and COPD Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Drugs for Asthma and COPD Revenue Breakdown by Type (2018-2029)
3 Drugs for Asthma and COPD Market Overview by Application
3.1 Introduction
3.1.1 Asthma
3.1.2 COPD
3.2 Global Drugs for Asthma and COPD Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Drugs for Asthma and COPD Historic Market Size by Application (2018-2023)
3.2.2 Global Drugs for Asthma and COPD Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Drugs for Asthma and COPD Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Drugs for Asthma and COPD Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Drugs for Asthma and COPD Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Drugs for Asthma and COPD Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Drugs for Asthma and COPD Revenue Breakdown by Application (2018-2029)
4 Drugs for Asthma and COPD Competition Analysis by Players
4.1 Global Drugs for Asthma and COPD Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Drugs for Asthma and COPD as of 2022)
4.3 Date of Key Players Enter into Drugs for Asthma and COPD Market
4.4 Global Top Players Drugs for Asthma and COPD Headquarters and Area Served
4.5 Key Players Drugs for Asthma and COPD Product Solution and Service
4.6 Competitive Status
4.6.1 Drugs for Asthma and COPD Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 GSK
5.1.1 GSK Profile
5.1.2 GSK Main Business
5.1.3 GSK Drugs for Asthma and COPD Products, Services and Solutions
5.1.4 GSK Drugs for Asthma and COPD Revenue (US$ Million) & (2018-2023)
5.1.5 GSK Recent Developments
5.2 AstraZeneca
5.2.1 AstraZeneca Profile
5.2.2 AstraZeneca Main Business
5.2.3 AstraZeneca Drugs for Asthma and COPD Products, Services and Solutions
5.2.4 AstraZeneca Drugs for Asthma and COPD Revenue (US$ Million) & (2018-2023)
5.2.5 AstraZeneca Recent Developments
5.3 Boehringer Ingelheim
5.3.1 Boehringer Ingelheim Profile
5.3.2 Boehringer Ingelheim Main Business
5.3.3 Boehringer Ingelheim Drugs for Asthma and COPD Products, Services and Solutions
5.3.4 Boehringer Ingelheim Drugs for Asthma and COPD Revenue (US$ Million) & (2018-2023)
5.3.5 Vertex Recent Developments
5.4 Vertex
5.4.1 Vertex Profile
5.4.2 Vertex Main Business
5.4.3 Vertex Drugs for Asthma and COPD Products, Services and Solutions
5.4.4 Vertex Drugs for Asthma and COPD Revenue (US$ Million) & (2018-2023)
5.4.5 Vertex Recent Developments
5.5 Roche
5.5.1 Roche Profile
5.5.2 Roche Main Business
5.5.3 Roche Drugs for Asthma and COPD Products, Services and Solutions
5.5.4 Roche Drugs for Asthma and COPD Revenue (US$ Million) & (2018-2023)
5.5.5 Roche Recent Developments
5.6 Novartis
5.6.1 Novartis Profile
5.6.2 Novartis Main Business
5.6.3 Novartis Drugs for Asthma and COPD Products, Services and Solutions
5.6.4 Novartis Drugs for Asthma and COPD Revenue (US$ Million) & (2018-2023)
5.6.5 Novartis Recent Developments
5.7 Teva
5.7.1 Teva Profile
5.7.2 Teva Main Business
5.7.3 Teva Drugs for Asthma and COPD Products, Services and Solutions
5.7.4 Teva Drugs for Asthma and COPD Revenue (US$ Million) & (2018-2023)
5.7.5 Teva Recent Developments
5.8 Chiesi
5.8.1 Chiesi Profile
5.8.2 Chiesi Main Business
5.8.3 Chiesi Drugs for Asthma and COPD Products, Services and Solutions
5.8.4 Chiesi Drugs for Asthma and COPD Revenue (US$ Million) & (2018-2023)
5.8.5 Chiesi Recent Developments
5.9 Mylan
5.9.1 Mylan Profile
5.9.2 Mylan Main Business
5.9.3 Mylan Drugs for Asthma and COPD Products, Services and Solutions
5.9.4 Mylan Drugs for Asthma and COPD Revenue (US$ Million) & (2018-2023)
5.9.5 Mylan Recent Developments
5.10 Sumitomo Dainippon
5.10.1 Sumitomo Dainippon Profile
5.10.2 Sumitomo Dainippon Main Business
5.10.3 Sumitomo Dainippon Drugs for Asthma and COPD Products, Services and Solutions
5.10.4 Sumitomo Dainippon Drugs for Asthma and COPD Revenue (US$ Million) & (2018-2023)
5.10.5 Sumitomo Dainippon Recent Developments
5.11 Merck
5.11.1 Merck Profile
5.11.2 Merck Main Business
5.11.3 Merck Drugs for Asthma and COPD Products, Services and Solutions
5.11.4 Merck Drugs for Asthma and COPD Revenue (US$ Million) & (2018-2023)
5.11.5 Merck Recent Developments
5.12 Beximco
5.12.1 Beximco Profile
5.12.2 Beximco Main Business
5.12.3 Beximco Drugs for Asthma and COPD Products, Services and Solutions
5.12.4 Beximco Drugs for Asthma and COPD Revenue (US$ Million) & (2018-2023)
5.12.5 Beximco Recent Developments
6 North America
6.1 North America Drugs for Asthma and COPD Market Size by Country (2018-2029)
6.2 the United States
6.3 Canada
7 Europe
7.1 Europe Drugs for Asthma and COPD Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Asthma and COPD Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Drugs for Asthma and COPD Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Asthma and COPD Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Drugs for Asthma and COPD Market Dynamics
11.1 Drugs for Asthma and COPD Industry Trends
11.2 Drugs for Asthma and COPD Market Drivers
11.3 Drugs for Asthma and COPD Market Challenges
11.4 Drugs for Asthma and COPD Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
